Has Shoba Kankipati received payments from drug or device companies?

Yes. Drug and device makers reported $34,814 in general payments to Shoba Kankipati across 516 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shoba Kankipati did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shoba Kankipati come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shoba Kankipati

Hematology & Oncology · Pleasant Hill, CANPI 1356392781

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 56.0% of the total. Reporting peaked in 2019 at $22,976 and has fallen 95.4% since, to $1,050 in 2024.

$34,814in general payments, 2019–2025

Across 516 payments — averaging $67.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Takeda Pharmaceuticals U.S.A., Inc.$19K
Seagen Inc.$4K
AstraZeneca$2K
Gilead$1K
Immunomedics, Inc.$1K
Pfizer$735
plus $7K from 52 others

What the payments were for

Consulting fees$3,42510%
Speaking & faculty fees$19,55056%
Travel & lodging$1,6035%
Food & beverage$9,65528%
Education$5812%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	39	$19,495
Seagen Inc.	29	$3,586
AstraZeneca(2 entities)	34	$1,883
Gilead(2 entities)	16	$1,319
Immunomedics, Inc.	1	$1,000
Pfizer	45	$735
E.r. Squibb & Sons, L.L.C.	51	$615
Novartis	27	$553
Johnson & Johnson(2 entities)	31	$515
Lilly USA, LLC	20	$485
Amgen	18	$439
Merck	24	$420
Genentech USA, Inc.	18	$385
Pharmacyclics LLC, An Abbvie Company	14	$325
Bristol Myers Squibb	14	$308
Astellas Pharma US Inc	12	$265
Eisai Inc.	10	$195
Puma Biotechnology, Inc.	7	$170
Clovis Oncology, Inc.	9	$156
Daiichi Sankyo Inc.	7	$143
Epizyme, Inc.	8	$137
Tesaro, Inc.	5	$131
Boehringer Ingelheim	7	$110
Rigel Pharmaceuticals, Inc.	5	$105
GSK	5	$100
Sanofi	5	$99
Beigene USA, Inc.	5	$99
Intuitive Surgical	2	$83
Blueprint Medicines Corporation	3	$71
Sanofi-aventis U.S. LLC	3	$65
Exelixis Inc.	2	$62
Incyte Corporation	3	$61
Taiho Oncology, Inc.	3	$56
Bard Peripheral Vascular, Inc.	1	$55
Regeneron Healthcare Solutions, Inc.	2	$50
Aurobindo Pharma USA, Inc.	3	$48
Array Biopharma Inc	3	$42
Heron Therapeutics, Inc.	2	$40
Deciphera Pharmaceuticals Inc.	2	$39
Global Blood Therapeutics, Inc.	2	$38
EMD Serono, Inc.	2	$31
Karyopharm Therapeutics Inc.	1	$27
Bayer	1	$24
AbbVie	1	$24
Agios Pharmaceuticals, Inc.	1	$23
Foundation Medicine, Inc.	1	$21
Acceleron Pharma, Inc.	1	$19
Dova Pharmaceuticals	1	$18
Acrotech Biopharma Inc.	1	$17
Ipsen Biopharmaceuticals, Inc	1	$16
Jazz Pharmaceuticals Inc.	1	$16
Stemline Therapeutics Inc.	1	$15
Myovant Sciences Inc.	1	$14
Sirtex Medical Inc	1	$14
Sun Pharmaceutical Industries Inc.	1	$13
Davol Inc.	1	$12
Advanced Accelerator Applications	1	$12
Paratek Pharmaceuticals, Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NINLARO$18,808
ADCETRIS$1,625
TUKYSA$1,375
IMFINZI$1,050
Trodelvy$1,000
INLYTA$124
LYNPARZA$124
TAGRISSO$111

How this compares

$34,814 in reported general payments places this provider in the 85th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Other hematology & oncology in Pleasant Hill

Dennis SlamonLos Angeles$3.1M
Sandra HorningStanford$2.5M
Mohammadbagher ZiariCorona$2.5M
George YaghmourLos Angeles$1.9M
Robert VescioWest Hollywood$1.1M
Kevin KellyLos Angeles$894K
Johnny ChangEncino$884K
Nitin RohatgiSacramento$814K
Omid HamidSanta Monica$809K
Catherine CoombsOrange$786K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →